Massachusetts eHealth Collaborative

maehc.org

The Massachusetts eHealth Collaborative (MAeHC) is a pioneer and national leader in health information technology. We assist for-profit and non-profit private organizations, government agencies, and multi-stakeholder collaborative to plan, deploy, operate, and optimize health information systems. Our services range from electronic health records (EHR) implementations to health information exchange (HIE) to quality data extraction, warehousing, analytics, and reporting.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INNATOSS LABORATORIES LAUNCHES NEUTRALIZING ANTIBODY TESTING SERVICE AGAINST SARS-COV-2 USING GENSCRIPT'S CPASS ™ KIT

Innatoss Laboratories | September 15, 2020

news image

Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service...

Read More

MEDTECH

OUTCOMES4ME PARTNERS WITH INVITAE TO OFFER GENETIC TESTING TO BREAST CANCER PATIENTS

Outcomes4Me | October 12, 2021

news image

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Me’s 360-degree, validated and evidence-based cancer support and tr...

Read More

MEDICAL

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

news image

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More

INDUSTRIAL IMPACT

SARTORIUS STEDIM BIOTECH COMPLETES ACQUISITION OF NOVASEP'S CHROMATOGRAPHY DIVISION

Sartorius Stedim Biotech S.A. | February 08, 2022

news image

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced today that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 e...

Read More
news image

INNATOSS LABORATORIES LAUNCHES NEUTRALIZING ANTIBODY TESTING SERVICE AGAINST SARS-COV-2 USING GENSCRIPT'S CPASS ™ KIT

Innatoss Laboratories | September 15, 2020

Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service...

Read More
news image

MEDTECH

OUTCOMES4ME PARTNERS WITH INVITAE TO OFFER GENETIC TESTING TO BREAST CANCER PATIENTS

Outcomes4Me | October 12, 2021

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Me’s 360-degree, validated and evidence-based cancer support and tr...

Read More
news image

MEDICAL

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More
news image

INDUSTRIAL IMPACT

SARTORIUS STEDIM BIOTECH COMPLETES ACQUISITION OF NOVASEP'S CHROMATOGRAPHY DIVISION

Sartorius Stedim Biotech S.A. | February 08, 2022

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced today that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 e...

Read More